TacticScaleWhat Haemonetics Does & How It Makes Money (HAE)
Updated October 2026 · reflects Haemonetics's latest reported financials
Medical technology company for plasma collection, blood management, and hospital devices. It sells collection and analysis equipment, and earns recurring revenue from the disposables, cartridges and software used with them, through a direct sales force and independent distributors to plasma centers, blood centers and hospitals.
How Haemonetics makes money
It sells collection and analysis equipment, and earns recurring revenue from the disposables, cartridges and software used with them, through a direct sales force and independent distributors to plasma centers, blood centers and hospitals.
What Haemonetics does
Haemonetics Corporation is a Boston-based medical technology company founded in 1971 that operates through Plasma, Blood Center and Hospital segments. In plasma, it supplies the NexSys PCS plasmapheresis system with related disposables and solutions, along with IT platforms such as NexLynk DMS and Donor360 that help plasma operators manage donors, operations and supply chain. Its hospital business covers blood and procedure-related technologies: TEG 6s viscoelastic analyzers and TEG Manager software for hemostasis assessment, Cell Saver Elite + for autologous blood recovery in surgery, VASCADE collagen-based vascular closure devices, transfusion management solutions, and sensor-guided guidewires like SavvyWire for TAVR and OptoWire for measuring pressure in heart arteries. It sells through a direct sales force and independent distributors.
Products & services
- NexSys PCS plasmapheresis system
- NexLynk DMS donor management system
- TEG 6s hemostasis analyzer
- Cell Saver Elite +
- VASCADE vascular closure
- SavvyWire TAVR guidewire
What is Haemonetics worth?
On an owner-earnings DCF, Haemonetics's most-likely value is about $159 versus a recent price near $119 (34% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$69) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Hualan Biological Engineering (002007.SZ) · Penumbra (PEN) · ADMA Biologics (ADMA) · Pacific Shuanglin Bio-pharmacy (000403.SZ) · GE HealthCare Technologies (GEHC)